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Abstract Behavioral and psychological symptoms of demen-
tia (BPSD) include apathy, sleep problems, irritability, wander-
ing, elation, agitation/aggression, and mood disorders such as
depression and/or anxiety. Elderly patients are usually treated
with second-generation antipsychotics; however, they present
not enough efficacy against all symptoms observed. Hence,
there still is an unmet need for novel pharmacotherapeutic
agents targeted BPSD. A novel arylsulfonamide derivative
ADN-1184 has been developed that possesses a preclinical
profile of activity corresponding to criteria required for treat-
ment of both psychosis and depressive symptoms of BPSD
without exacerbating cognitive impairment or inducing motor
disturbances. To broaden its pharmacological efficacy toward
anxiety symptoms, its anxiolytic properties have been exam-
ined in common animal preclinical models in rats and mice.
ADN-1184 significantly increased the number of entries into
open armsmeasured in the elevated plus-maze test; however, it
simultaneously increased parameters of exploratory activity. In
the Vogel conflict drinking test, ADN-1184 dose-dependently
and significantly increased the number of shocks accepted and
the number of licks. Moreover, in mice, it also had specific
anxiolytic-like activity in the four-plate test, and only negligi-
ble one at a specific mid-range dose measured in the
spontaneous marble burying test. The obtained findings reveal
that ADN-1184 displays anxiolytic-like activity in animal
models of anxiety which employed punished stimuli. In its
unusual combination of some anxiolytic action with already
proven antipsychotic and antidepressant properties, and lack of
any disruptive impact on learning and memory processes and
motor coordination, ADN-1184 displays a profile that would
be desired for a novel therapeutic for BPSD.
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Introduction
Dementia is a clinical syndrome that expresses itself in three
areas, i.e., cognitive deficits, psychological and behavioral
disturbances, and difficulties in carrying out daily functions
(De Deyn and Wirshing 2001). Behavioral and psychological
symptoms of dementia (BPSD) include apathy, sleep prob-
lems, irritability, wandering, elation, agitation/aggression,
andmood disorders such as depression and/or anxiety. At least
one symptom of BPSD is reported in about 80% patients with
dementia (Proitsi et al. 2011). The prevalence of anxiety is
rated as 38 % in Alzheimer disease and up to 72 % in vascular
dementia (Ballard et al. 2000).
BPSD affect the quality of life of older people and their
caregivers. Pharmacological treatment ought to be considered
when first-line non-pharmacological management fails or
when there is a significant risk (e.g., physical aggression, ag-
itation, or psychosis) (Cheung and Stapelberg 2011). Elderly
patients are usually treated with second-generation antipsy-
chotics (SGAs) that produce fewer extrapyramidal side-
effects and have better efficacy against negative symptoms
than classical neuroleptics (Byerly et al. 2001; Liperoti et al.
2008; Kołaczkowski et al. 2014b). Despite the global and
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embedded use of antipsychotics for BPSD treatment, the ev-
idence and rationale for the use of this drug class is proven to
be modest.
A recent meta-analysis based on 14 placebo-controlled
trials of elderly patients with BPSD revealed only modest
positive effects for risperidone, olanzapine, and
aripiprazole, all SGAs (Maher et al. 2011). Moreover,
SGAs may produce adverse effects including cardiovas-
cular and metabolic ones (Nobili et al. 2009; Schulze
et al. 2013). These drugs may also worsen cognitive func-
tion, especially in the case of elderly patients who already
suffer from memory deficits (Jeste et al. 2008; Vigen et al.
2011). Some SGAs might be an option for the treatment
of depressive symptoms (Moller 2000, 2005a, b; Leucht
et al. 2009); however, they were not developed to provide
alleviation of mood deficits in elderly patients. There still
is an unmet need for novel pharmacotherapeutic agents
targeted for treatment of BPS—an increasingly challeng-
ing problem connected with the aging populations in
many developed countries.
In Kołaczkowski et al. (2014a), we described a novel
arylsulfonamide derivative (ADN-1184) that possesses a pre-
clinical profile of activity corresponding to criteria required
for treatment of both psychosis and depressive symptoms of
BPSDwithout exacerbating cognitive impairment or inducing
motor disturbances. As no animal model of BPSD is available,
ADN-1184’s potential antipsychotic properties have been
evaluated in a range of procedures, including hyperactivity
and stereotypies induced by MK-801, procedures relevant to
dementia patients who suffer from psychoses of glutamatergic
origin (Bardin et al. 2007; Siegel 1978) as well as conditioned
avoidance response (Kołaczkowski et al. 2014a). In all these
models, ADN-1184 demonstrated an antipsychotic-like po-
tency similar to or even stronger than that produced by
SGAs and tested in the same experimental conditions
(Kołaczkowski et al. 2014a). Moreover, ADN-1184 was also
active in a classic model of potential antidepressant activity—
the forced swim test—showing potency of the same order of
magnitude as that of imipramine. Furthermore, its active anti-
depressant doses were lower than those in models of
antipsychotic-like activity. Simultaneously, ADN-1184 did
not impair the passive avoidance response in contrast to
SGAs, which elicited dose-dependent disruption in that mod-
el. While being active in models of psychosis, mood deficit
and memory performance, ADN-1184 additionally did not
elicit catalepsy or a decrease in locomotor activity when ad-
ministered at antipsychotic and antidepressant doses. ADN-
1184 only began to decrease locomotor action at a dose of
30 mg/kg and, at the same dose, weakly elicited catalepsy
(Kołaczkowski et al. 2014a).
ADN-1184 in vivo profile, combining antipsychotic- and
antidepressant-like activities without cognitive or motor im-
pairments, appears to stem from its unusual receptor
combination resulting from potent blockade of 5-HT6, 5-
HT7, and 5-HT2A receptors, and modest antagonism of dopa-
mine D2 and D3 receptors in the absence of anticholinergic
effects. ADN-1184 also antagonizes α1-adrenergic receptors
which may contribute to its antipsychotic efficacy, widens the
therapeutic windowwith regard to extrapyramidal side-effects
(Wadenberg et al. 2000), and helps to reduce agitation and
aggressive behavior (Wang et al. 2009) seen in elderly patients
with BPSD. Antagonism of peripheral α1-adrenergic recep-
tors is associatedwith adverse cardiovascular effects, especial-
ly in elderly people; thus, this needs to be taken into consid-
eration in the treatment of patients with potentially fragile
cardiac function.
The above observations suggest that the combined
multireceptor functional profile of ADN-1184 and its po-
tential antipsychotic/antidepressant action observed in rats
might offer an effective and broad-based platform for the
control of mood deficit states. Inasmuch as anxiety is a
common and comorbid symptom of depression, the pres-
ent work discusses the potential anxiolytic-like activity of
ADN-1184 detected in a wide range of rodent preclinical
models of anxiety. Its activity has been compared to ac-
tion of three SGAs (risperidone, olanzapine, and
aripiprazole) for which small but statistically significant
benefits have been observed in a recent meta-analysis
(Maher et al. 2011) for the treatment of behavioral symp-
toms associated with dementia in elderly patients.
Materials and methods
Animals
The experiments were conducted on male Wistar rats (230–
300 g) purchased from Charles River Laboratories (Germany)
and male Albino Swiss mice (21–25 g) obtained from a li-
censed breeder (Staniszewska, Poland). Animals were kept in
a group of four (rats) or 10 (mice) in standard plastic cages and
housed in a room under controlled conditions (temperature 21
± 2 °C, humidity 50–60 %, under a 12-h light/dark cycle,
lights on at 8.00 a.m.). Standard lab chow (Labofeed H,
WPiK, Kcynia, Poland) and tap water were available ad
libitum unless otherwise stated. All investigations were per-
formed between 9:00 a.m. and 4:00 p.m. in soundproof exper-
imental rooms under dim light and continuous white noise
(65 dB). Behavioral parameters were recorded automatically
by microcomputers or manually scored by observers unaware
of the treatment applied. Tested animals were used only once.
Treatment of animals in the present studies was in full accor-
dance with the ethical standards laid down in respective Polish
and European (Directive no. 86/609/EEC) regulations. All
procedures were approved by a local ethics committee.
594 Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:593–602
Drugs
ADN-1184 (hydrochloride salt), risperidone, olanzapine,
and aripiprazole provided by Adamed Ltd. (Pieńków,
Poland), were suspended in a 1 % Tween 80 (Sigma-
Aldrich) and administered intraperitoneally (i.p.) in a vol-
ume of 2 ml/kg (rats) or 10 ml/kg (mice). The drugs were
injected 60 min (rats) or 30 min (mice) before the experiment.
Control animals received vehicle according to the same
procedure. All solutions were prepared immediately prior to
use and protected from the light.
Behavioral procedures in rats
Elevated plus-maze (EPM) test
The testing procedure was based on a method described by
Pellow and File (1986). EPM test is an Bunconditional^
anxiety-like test based on rodents’ natural aversion to heights
and open spaces. Plus-maze apparatus (an automated device
produced by Campden Instruments Ltd. (UK) made of dura-
ble, high density, non-porous black plastic, elevated to a
height of 50 cm, consisted of two open arms (50×10 cm)
and two closed arms (50 ×10 cm, and 30-cm high walls),
arranged so that the two arms of each type were opposite each
other. Floor of the plus-maze was made of infrared transpar-
ent material what means that there are no visible sensors.
Plus-maze apparatus was connected to PC software by con-
trol chassis. The experiments were conducted under dim
light (only the center of the maze was illuminated with
low-intensity light 30 lux measured on the maze level) and
continuous white noise (65 dB). Each rat was gently placed
in the center of the plus-maze, facing one of the closed arms,
immediately after a 5-min adaptation period in a plastic
black box (60×60×35 cm), to increase the overall activity
in the EPM. During a 5-min test period, automated Motor
Monitor System recorded the number of entries into the
closed and open arms and the time spent in either type of
the arms. The device counted an effective arm-entry when
the four paws of a rat were into any arm. The maze was
thoroughly cleaned after each trial.
Exploratory activity measured in the EPM test
To assess an influence of a tested compound on general ex-
ploratory activity of rats and to control possible changes with-
in, total ambulation (the total distance covered by a rat, and
ambulation along X and Yaxis) was taken during a 5-min test
period (i.e., the time equal to the observation period in the
EPM test). The experiment was performed using EPM appa-
ratus (details see above).
Vogel conflict drinking test
The testing procedure based on a method described by Vogel
et al. (1971) was performed using AnxietyMonitoring System
BVogel test^ produced by TSE Systems. Apparatus was
consisted of a polycarbonate cage (dimensions 26.5 _15 _
42 cm), equipped with a grid floor made from stainless steel
bars and a drinking bottle containing tap water. Experimental
chambers (two) were connected to PC software by control
chassis and a device that generates electric shocks. In this
Bconditional^ model, an electric shock as noxious stimulus
is applied. The testing procedure consisted of 2-day
habituation/adaptation and an exact test. On the first day of
the experiment, the rats were adapted to the test chamber for
10-min adaptation period during which they had free access to
the drinking bottle followed by a 24-h water deprivation peri-
od. Afterwards, they were allowed a 30-min free-drinking
session in their home cages. This protocol of 24-h deprivation
and adaptation period was repeated on the second day. On the
third day, animals were place again in the test chamber 60 min
after administration of vehicle/ADN-1184 and were given free
access to drinking bottle during 5 min. Recording the data
started immediately after the first lick, and every 20 licks rats
were punished with an electric shock (0.5 mA, lasting 1 s).
The impulses were released via the spout of the drinking bot-
tle. The number of licks and the number of shocks received
throughout a 5-min experimental session were recorded
automatically.
Hot plate and free-drinking tests
To exclude possible drug-induced changes in shock sensitivity
or an increasing influence on thirst drive which can lead to
false positive results in the Vogel conflict drinking test, stim-
ulus threshold and water consumption during a free-drinking
session were determined in separate groups of rats. In either of
those two studies, the rats were manipulated similarly to the
Vogel conflict drinking test, including two 24-h water depri-
vation periods separated by 10-min adaptation session in ex-
perimental cages and 30-min of water availability in their
home cages. In the free-drinking test, each animal was
allowed to freely drink from the drinking bottle and the
amount of water (g) consumed during 5 min was recorded
for each rat. The pain threshold was evaluated using hot plate
test (Commat Ltd, Turkey) in rats. The plate was enclosed
with a transparent Plexiglass cylinder (35-cm high) to
keep the animal on the heated surface of the plate. The
latency to pain reaction (lick a hind paw or jumping)
when the rat was placed on a hot plate (52.5 ± 0.5 °C,
19-cm diameter) was measured. The rat was removed
from the plate immediately upon visible pain reaction or
if no response occurred within 30 s.
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Behavioral procedures in mice
Four-plate test (4-PT)
The four-plate apparatus (BIOSEB) consists of a cage
(25×18×16 cm) floored by four identical rectangular metal
plates (8×11 cm) separated from one another by a gap of
4 mm. The top of the cage is covered by a transparent
Perspex lid that prevents escape behavior. The plates are con-
nected to a device that can generate electric shocks. Following
a 15-s habituation period, the animal’s motivation to explore a
novel environment is suppressed by an electric foot shock
(0.8 mA, 0.5 s) every time it moves from one plate to another
during a 1-min test session. This action is referred to as a
Bpunished crossing^ and is followed by a 3-s shock interval,
during which the animal can move across plates without re-
ceiving a shock (Aron et al. 1971).
Marble burying test (MBT)
The test was performed based on a method described by
Broekkamp et al. (1986) with minor modifications. Mice were
placed individually into plastic cages which were identical to
their home cage containing a 5-cm layer of sawdust and 20
marbles (1.4-cm diameter) evenly spaced against the wall.
After 30-min experimental period, mice were removed from
cages and the number of marbles at least 2/3 buried was count-
ed. The experiment was conducted on Albino Swiss mice.
Data analysis
All the data are presented as the mean±SEM. The statistical
significance of the results was evaluated by a one-way analy-
sis of variance (ANOVA), followed by Bonferroni’s compar-
ison test (statistical significance set at p<0.05). The data from
the hot plate and free-drinking test was analyzed using a t test.
The Statistica 10.0 software package for Windows (StatSoft,
Tulsa, OK, USA) was used to analyze all data.
Results
EPM test
ADN-1184 at a dose of 0.3 mg/kg only, increased signifi-
cantly the number of entries into the open arms. Risperidone
at doses of 0.03 and 0.1 mg/kg statistically increased the
percentage of entries into open arms. Olanzapine and
Table 1 Anxiolytic-like effects of the tested compounds in the EPM test in rats
Treatment Dose
(mg/kg)
Time (s) spent
in the open arms
Percentage of time spent
in the open arms
Number of entries
into the open arms
Percentage of entries
into the open arms
Vehicle ADN-1184 0 49.2 ± 7.4 25.7 ± 3.5 10.6 ± 2.0 31.6 ± 5.1
0.1 68.8 ± 6.3 34.0 ± 5.4 13.1 ± 1.4 32.5 ± 4.4
0.3 87.8 ± 11.4 44.0 ± 4.8 18.2 ± 2.2* 37.8 ± 2.8
1 78.3 ± 2.4 36.0 ± 5.6 15.3 ± 1.6 37.8 ± 3.9
3 73.5 ± 15.1 35.3 ± 2.9 11.0 ± 1.0 45.6 ± 4.6
F(4,29) = 1.838, NS F(4,29) = 2.122, NS F(4,29) = 3.365, p< 0.05 F(4,29) = 1.866, NS
Vehicle Risperidone 0 43.1 ± 10.1 19.0 ± 4.9 8.5 ± 2.8 21.2 ± 4.5
0.03 78.5 ± 11.3 33.6 ± 5.1 14.8 ± 2.1 38.0 ± 2.7*
0.1 79.9 ± 8.9 33.1 ± 3.7 16.0 ± 1.7 37.3 ± 2.4*
0.3 95.1 ± 19.4 40.4 ± 8.2 12.7 ± 2.1 36.4 ± 4.8
F(3,25) = 2.515, NS F(3,25) = 2.244, NS F(3,25) = 2.145; NS F(3,25) = 4.535, p< 0.05
Vehicle Olanzapine 0 84.3 ± 19.6 33.0 ± 7.5 13.0 ± 1.8 35.5 ± 5.3
0.03 50.0 ± 12.8 19.8 ± 5.2 7.8 ± 1.1 29.1 ± 3.4
0.1 94.8 ± 9.0 40.1 ± 4.4 16.3 ± 2.6 37.0 ± 6.0
0.3 71.3 ± 12.3 27.8 ± 5.1 11.9 ± 2.4 40.5 ± 3.9
F(3,25) = 2.118, NS F(3,25) = 2.521, NS F(3,25) = 3.070, p< 0.05 F(3,25) = 1.183, NS
Vehicle Aripiprazole – 97.3 ± 20.6 40.4 ± 8.6 17.6 ± 4.0 39.0 ± 6.9
0.3 123.8 ± 13.5 52.5 ± 4.7 18.8 ± 2.2 52.2 ± 4.5
1 75.5 ± 14.7 32.6 ± 6.2 13.7 ± 1.9 36.4 ± 5.0
3 89.5 ± 36.4 33.5 ± 12.3 9.5 ± 1.8 33.0 ± 4.1
F(3,22) = 1.712, NS F(3,22) = 1.556, NS F(3,22) = 2.888, NS F(3,22) = 3.141, p< 0.05
ADN-1184, risperidone, olanzapine, and aripiprazole were injected i.p. 60 min before the test. Values represent the mean ± SEM during the 5-min test
session compared with vehicle group *p< 0.05 (ANOVA is followed by the Bonferroni’s post hoc test), N= 5–8
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aripiprazole produced no significant effects in that test; how-
ever, a tendency to increase the number of entries into open
arms and the percentage of entries into the open arms, re-
spectively, was observed (Table 1).
Exploratory activity measured in the EPM test
Both parameters, i.e., total entries and total distance travelled
presented in Table 2, measured simultaneously with
anxiolytic-like activity using the automated version of the
EPM, reflect general exploratory activity of rats. ADN-1184
at doses of 0.1, 0.3, and 1 mg/kg significantly increased one or
two of parameters measured. The tested compound adminis-
tered at a dose of 3 mg/kg had no influence on general explor-
atory activity. Similarly, all tested SGAs did not affect explor-
atory activity of rats measured in EPM (Table 2).
Vogel conflict drinking test
ADN-1184 at a dose of 3 mg/kg significantly increased the
number of shocks accepted (ANOVA F(3,25) = 5.391,
p<0.01) and the number of licks (ANOVA F(3,25)=5.761,
p<0.01) during 5-min experimental evaluation. Lower doses
of ADN-1184, i.e., 0.3 and 1mg/kgwere ineffective in that test
but the measured effect was dose-dependent (Figs. 1a and 2a).
Risperidone at a dose of 0.03 mg/kg (ANOVA F(2,
28) = 3.504, p < 0.01 and F(2,28) = 3.454, p < 0.01),
olanzapine at doses of 1 and 3 mg/kg (ANOVA F(3,
31) = 4.248, p < 0.05 and F(3,31) = 4.159, p < 0.05) and
aripiprazole at a dose of 10 mg/kg (ANOVA F(3,23)=6.079,
p<0.01 and F(3,23)=5.922, p<0.01) significantly increased
the number of shocks accepted and the number of licks mea-
sured in the Vogel test, respectively (Figs. 1b–d and 2b–d).
Hot-plate and free-drinking tests
ADN-1184, risperidone, olanzapine, and aripiprazole adminis-
tered at doses effective in the Vogel conflict drinking test, i.e.,
3, 0.03, 1, 3, and 10 mg/kg, respectively, had no effect on pain
reaction time measured in the hot plate test as well as they did
not change the amount of water consumed by deprived rats as
compared with control animals, during 5-min session (Table 3).
4-PT
ADN-1184 given at doses of 0.312, 0.625, and 1.25 mg/kg,
dose-dependently and significantly increased the number of
punished crossings (ANOVA F(4,42) = 5.023, p < 0.01).
There was no difference between control group and the dose
0.156 mg/kg of ADN-1184 (Fig. 3a). Risperidone at doses of
Table 2 Effects of the tested
compounds on exploratory
activity measured in the EPM in
rats
Treatment Dose (mg/kg) Total entries Total distance [cm]
Vehicle ADN-1184 0 29.0 ± 2.4 4613.0 ± 158.0
0.1 40.6 ± 3.5 5686.6 ± 201.1*
0.3 49.3 ± 4.5** 5944.5 ± 245.7**
1 41.8 ± 3.9* 5519.0 ± 282.6
3 25.9 ± 2.6 3777.9 ± 401.1
F(4,29) = 7.853, p< 0.001 F(4,29) = 11.292, p< .0001
Vehicle Risperidone 0 35.5 ± 7.0 4465.3 ± 462.0
0.03 39.9 ± 5.5 5268.0 ± 416.0
0.1 42.9 ± 3.7 5072.5 ± 318.0
0.3 35.1 ± 4.7 4524.7 ± 259.9
F(3,25) = 0.516; NS F(3,25) = 1.156; NS
Vehicle Olanzapine 0 38.2 ± 2.6 5078.7 ± 157.7
0.03 26.6 ± 1.9 4552.5 ± 198.0
0.1 43.4 ± 5.8 5401.1 ± 448.4
0.3 30.6 ± 6.1 4591.6 ± 355.2
F(3,25) = 2.680, NS F(3,25) = 1.653, NS
Vehicle Aripiprazole 0 43.4 ± 6.7 5613.8 ± 222.9
0.3 32.2 ± 6.5 4419.0 ± 467.4
1 38.4 ± 2.5 4792.0 ± 132.9
3 35.5 ± 2.8 4641.8 ± 260.9
F(3,22) = 0.960, NS F(3,22) = 2.651, NS
ADN-1184, risperidone, olanzapine and aripiprazole were injected i.p. 60min before the test. Values represent the
mean± SEM during the 5-min test session compared with vehicle group *p < 0.05 (ANOVA is followed by the
Bonferroni’s post hoc test), N= 6–8
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0.005 and 0.01 mg/kg produced anxiolytic-like activity mea-
sured in that test (ANOVA F(2,23) =4.963, p<0.05) while
higher doses significantly decreased the number of punished
crossings (ANOVA: F(3,36) = 9.013, p<0.0001) (Fig. 3b).
Olanzapine tested at doses of 0.25–2 mg/kg (ANOVA F(4,
53) = 3.123, p< 0.05) and aripiprazole at doses of 0.06–
0.5 mg/kg (ANOVA F(4,49)=4.856, p<0.01) produced no
statistical anxiolytic-like effect in that test. In the case of
aripiprazole, a tendency to increase the number of punished
crossings could be observed; however, the results did not
reach significant level (Fig. 3c, d).
MBT
ADN-1184 at a dose of 0.625 mg/kg only produced a signif-
icant decrease in the number of buried marbles (ANOVA F(4,
41) = 3.06, p < 0.05) during 30-min experimental period.
Other doses did not reach significant level of the effect
(Fig. 4a). Risperidone significantly decreased the number of
buried marbles after administration at a dose of 0.01 mg/kg
only (ANOVA F(3,34) = 6.563, p < 0.01) (Fig. 4b).
Olanzapine (ANOVA F(3,30) = 31.873, p < 0.00001) and
aripiprazole (ANOVA F(3,28) = 13.905, p<0.00001) given
at doses of 2.5 and 5 mg/kg significantly decreased the num-
ber of buried marbles (Fig. 4c, d).
Discussion
ADN-1184, a novel monoaminergic ligand with antipsychotic
and antidepressant activities (Kołaczkowski et al. 2014a), pos-
sesses a multitarget profile distinct from current atypical anti-
psychotic agents. Its dopamine D2 and D3 antagonist proper-
ties, together with its potent blockade of 5-HT6, 5-HT7 and 5-
HT2A receptors, and the absence of anticholinergic and anti-
histaminic effects, are consistent with a beneficial influence on
psychosis, cognition, and mood impairments. Inasmuch as
anxiety is a common and comorbid symptom of BPSD, we
examined the potential action of ADN-1184 in common ro-
dent models of anxiety to broaden its behavioral profile. We
used different anxiety procedures based on a variety of anxiety
stimuli. The EPM test is postulated to induce unconditioned
fear due to heights and open spaces, which seems to be con-
sistent with panic anxiety (Graeff et al. 1996). In this model,
ADN-1184 increased all parameters measured; however, it
only significantly increased the number of entries into open
arms after administration at a dose of 0.3 mg/kg.
Simultaneously, that dose of ADN-1184 increased parameters
of exploratory activity indicating that this is likely accounted
for the increased number of entries into the open arms.
Generalized anxiety disorder, a common, undertreated yet
incapacitating disorder reveals a chronic prognosis and is
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Fig. 1 Anxiolytic-like effect of the tested compounds in the Vogel
conflict drinking test in rats (the number of shocks accepted during
5 min). ADN-1184, risperidone, olanzapine, and aripiprazole were
injected i.p. 60 min before the test. Values represent the mean ± SEM
compared to the respective vehicle groups *p < 0.05; **p < 0.001
(ANOVA is followed by the Bonferroni’s post hoc test), N= 7–8
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frequently comorbid with other symptoms of BPSD (Liperoti
et al. 2008). This anxiety state is probably linked to a bias in
anticipating adverse circumstances, often without any obvious
threat (Steimer 2011). There are few, if any, animal models
sufficiently validated to discriminate among the various sub-
types of anxiety disorders. In general, operant conflict proce-
dures are pharmacologically isomorphic with the human state
of generalized anxiety (Schlaepfer and Nemeroff 2012).
Among these conditioned procedures, the Vogel test is of rath-
er broad significance to clinical anxiety, particularly to gener-
alized anxiety disorder (Millan and Brocco 2003). The
anxiolytic-like activity of ADN-1184 is clearly visible in the
Vogel conflict drinking test in rats, a Bconditional^ anxiety-
like paradigm. ADN-1184 dose-dependently and significantly
increased the number of shocks accepted and the number of
licks. Moreover, it presented specific anti-conflict action,
since ADN-1184 had an effect on neither the pain threshold
nor unpunished water consumption. ADN-1184 also had
specific anxiolytic-like activity in the FPT and only a
negligible effect in the MBT visible at a specific mid-
range dose. Thus, it appears that ADN-1184 clearly ex-
erts the anxiolytic-like effect in tests incorporating
punishing stimuli; however, it produces little or no ef-
fect in models based on innate anxiety in the EPM or
anxiety/compulsive-like behavior in the MBT.
In the present study, we compared the action of ADN-1184
with the effects produced by three SGAs—olanzapine,
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Fig. 2 Anxiolytic-like effect of the tested compounds in the Vogel
conflict drinking test in rats (the number of licks during 5 min). ADN-
1184, risperidone, olanzapine, and aripiprazole were injected i.p. 60 min
before the test. Values represent the mean ± SEM compared to the
respective vehicle groups *p < 0.05; **p < 0.001 (ANOVA is followed
by the Bonferroni’s post hoc test), N= 7–8
Table 3 Effects of the tested compounds in the hot plate and water
consumption tests in water-deprived rats
Treatment Dose Hot plate test Water consumption
(mg/kg) Time of reaction (s) (g/5 min))
Vehicle 0 8.1 ± 0.7 5.3 ± 0.3
ADN-1184 3 7.8 ± 0.9 5.6 ± 0.3
aF(1,12) = 0.844, NS aF(1,13) = 0.292, NS
Risperidone 0.03 7.1 ± 0.7 5.7 ± 0.9
aF(1,11) = 0.518, NS aF(1,12) = 1.006, NS
Olanzapine 1 8.4 ± 0.8 5.1 ± 0.4
3 8.6 ± 0.6 5.6 ± 0.5
bF(2,20) = 1.480, NS bF(2,22) = 0.964, NS
Aripiprazole 10 7.5 ± 0.8 5.4 ± 0.9
bF(1,12) = 0.960, NS bF(1,12) = 1.051, NS
ADN-1184, risperidone, olanzapine and aripiprazole were injected i.p.
60 min before the test. Values represent the mean± SEM of time reaction
in the hot plate test and amount of water consumed during 5 min test
session. The data were analyzed using a t test and b one-way ANOVA
followed by Bonferroni’s post hoc test, N= 7–8
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aripiprazole, and risperidone—since the recent meta-analysis
had revealed that all these drugs produced a small but signif-
icant improving effect on behavioral symptoms of dementia in
elderly patients (Maher et al. 2011). It is noteworthy that,
quantitatively, ADN-1184 was more efficacious in the FPT
in mice than olanzapine and aripiprazole studied under the
same conditions. However, in the EPM or MBT, it had no
appreciable effect but risperidone does or olanzapine and
aripiprazole do, respectively. In the rat Vogel model, ADN-
1184 showed superiority over aripiprazole when one con-
siders the active dose of both compounds. However, when
the magnitude of change is taken into account, the studied
compound did not present better parameters than the reference
antipsychotic drugs. Furthermore, anxiolytic-like activity of
ADN-1184 in both rats and mice was 10 to 30-fold weaker
than that of risperidone acting in low doses; however, risper-
idone has greater potency to induce adverse effects, e.g., cat-
alepsy and sedation, than ADN-1184 (Kołaczkowski et al.
2014a, b). These data deliver indications of accentuated
anxiolytic-like activity of ADN-1184, especially in models
employing punished stimuli; however, drawing definite con-
clusions about its clinical potency is premature. Generally,
animal tests and in this case, animal models of anxiety can
certainly be useful to find out more about a pharmacological
profile of newly developed compounds and biological bases
of anxiety disorders. These models certainly provide a lot of
information on the brain and behavioral mechanisms which
could be involved in the etiology and physiopathology of
anxiety disorders, but are usually not satisfactory when
confronted directly with clinical syndromes (Steimer 2011).
The neurobiological mechanisms that mediate the
anxiolytic-like action of ADN-1184 are not clear. Since
ADN-1184, similar to most SGAs, has a complex multiple-
receptor binding profile, it is difficult to pinpoint which recep-
tor action or actions account for its anxiolytic-like activity.
Nevertheless, given the in vitro pharmacological profile of
ADN-1184, it seems that 5-HT6 and/or 5-HT7 receptor antag-
onism is most probably involved in the anxiolytic-like effects
of this compound. Indeed, it was previously shown that both
the selective 5-HT6 and the selective 5-HT7 receptor antago-
nists displayed pronounced anti-anxiety effects, in the same
animal models as the ones used for characteristic of ADN-
1184 (Wesołowska and Nikiforuk 2007; Wesołowska et al.
2006). Furthermore, the described effects of 5-HT6 receptor
blockade were more pronounced and were suggested to be
connected with indirect enhancement of GABA-ergic trans-
mission (Wesołowska 2008). Future research should be direct-
ed at clarifying this issue.
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Fig. 3 Anxiolytic-like effect of the tested compounds in the 4-PT in
mice. ADN-1184, risperidone, olanzapine, and aripiprazole were
injected i.p. 30 min before the test. Values represent the mean ± SEM
compared to a vehicle group *p < 0.05; **p < 0.01 (ANOVA is
followed by the Bonferroni’s post hoc test), N= 8–11
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In conclusion, the obtained findings reveal that ADN-1184
displays anxiolytic-like activity in animal models of anxiety
which employed punished stimuli. In its unusual combination
of some anxiolytic action with already proven antipsychotic
and antidepressant properties, and lack of any disruptive im-
pact on learning and memory processes and motor coordina-
tion, ADN-1184 displays a profile, that would be desired for a
novel therapeutic for BPSD. Additionally, considering any
further development of pharmacotherapeutics to treat BPSD,
one should bear in mind that the use of antipsychotic drugs in
BPSD is limited by boxed warnings issued by the US Food
and Drug Administration. The warnings added to the package
inserts of SGAs emphasize the risk of serious adverse effects
that can be induced by these drugs in elderly patients
(Schneider et al. 2006; Schulze et al. 2013). Hence, meeting
the need for efficacious medications to treat BPSD would
require a continuous discussion between preclinical and clin-
ical researchers as well as regulatory bodies and development
of guidelines indicating strategies for evaluation of novel
compounds with safer therapeutic profiles (Kołaczkowski
et al. 2014a).
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